BioLife Solutions Inc (NASDAQ:BLFS) CFO Sells $568,800.00 in Stock

BioLife Solutions Inc (NASDAQ:BLFS) CFO Greef Roderick De sold 30,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $18.96, for a total value of $568,800.00. Following the sale, the chief financial officer now directly owns 35,859 shares in the company, valued at $679,886.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Greef Roderick De also recently made the following trade(s):

  • On Wednesday, July 31st, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The stock was sold at an average price of $19.17, for a total value of $191,700.00.
  • On Monday, July 1st, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.23, for a total value of $172,300.00.
  • On Wednesday, July 3rd, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The stock was sold at an average price of $16.09, for a total value of $160,900.00.
  • On Wednesday, June 19th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.60, for a total value of $176,000.00.
  • On Thursday, May 23rd, Greef Roderick De sold 14,500 shares of BioLife Solutions stock. The stock was sold at an average price of $17.88, for a total value of $259,260.00.
  • On Thursday, May 16th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The stock was sold at an average price of $16.76, for a total value of $167,600.00.

BLFS traded down $0.99 during trading on Friday, hitting $18.40. The company’s stock had a trading volume of 161,800 shares, compared to its average volume of 172,640. The company has a quick ratio of 12.99, a current ratio of 14.50 and a debt-to-equity ratio of 0.02. BioLife Solutions Inc has a twelve month low of $9.15 and a twelve month high of $26.35. The business’s fifty day moving average price is $17.31. The company has a market cap of $360.38 million, a price-to-earnings ratio of 130.00 and a beta of 1.31.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. The company had revenue of $5.77 million for the quarter, compared to analyst estimates of $5.67 million. Equities research analysts forecast that BioLife Solutions Inc will post 0.13 earnings per share for the current year.

Several research firms recently commented on BLFS. BidaskClub raised BioLife Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, July 23rd. HC Wainwright assumed coverage on BioLife Solutions in a report on Monday, July 22nd. They issued a “buy” rating and a $23.00 price objective on the stock. Northland Securities reissued a “buy” rating and issued a $18.00 price objective on shares of BioLife Solutions in a report on Tuesday, July 9th. ValuEngine raised BioLife Solutions from a “hold” rating to a “buy” rating in a report on Monday, July 22nd. Finally, Zacks Investment Research lowered BioLife Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. BioLife Solutions currently has an average rating of “Buy” and an average price target of $18.67.

Institutional investors and hedge funds have recently modified their holdings of the business. Cowen Prime Services LLC acquired a new stake in BioLife Solutions in the first quarter valued at approximately $63,000. Signaturefd LLC purchased a new position in shares of BioLife Solutions in the first quarter valued at approximately $161,000. Conestoga Capital Advisors LLC purchased a new position in shares of BioLife Solutions in the first quarter valued at approximately $238,000. Spears Abacus Advisors LLC purchased a new position in shares of BioLife Solutions in the first quarter valued at approximately $243,000. Finally, Magnus Financial Group LLC purchased a new position in shares of BioLife Solutions in the first quarter valued at approximately $307,000. 45.94% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Story: How to use beta for portfolio diversification

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.